Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zentalis Pharmaceuticals ( (ZNTL) ) has issued an update.
Zentalis Pharmaceuticals announced on December 15, 2025, that it has entered into a Stock Purchase Agreement with Matrix Capital Master Fund, LP to repurchase 7,500,000 shares of its common stock at a discounted price of $1.33 per share. This repurchase is part of Matrix Capital Management’s plan to wind down its family of funds, and Zentalis does not anticipate this transaction will significantly affect its cash runway, which is projected to extend into late 2027.
The most recent analyst rating on (ZNTL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Zentalis Pharmaceuticals stock, see the ZNTL Stock Forecast page.
Spark’s Take on ZNTL Stock
According to Spark, TipRanks’ AI Analyst, ZNTL is a Neutral.
Zentalis Pharmaceuticals faces significant financial hurdles, with consistent losses and negative cash flows. Technical indicators also show weak momentum. However, recent positive clinical developments provide a glimmer of hope for future growth. Despite the financial and technical challenges, the potential of azenosertib in treating aggressive cancers could offer strategic value, albeit with high risk.
To see Spark’s full report on ZNTL stock, click here.
More about Zentalis Pharmaceuticals
Average Trading Volume: 656,625
Technical Sentiment Signal: Strong Sell
Current Market Cap: $101.2M
For an in-depth examination of ZNTL stock, go to TipRanks’ Overview page.